Into This World We're Thrown
NCT04842812
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2, Mesothelin+, MUC1, GPC3, LeY, AXL, EGFR, ROR1+, GD1/2, B7-H3
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy
Gender: All
Age: 18 Years to 85 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes:
Exclusions:
https://ClinicalTrials.gov/show/NCT04842812
NCT03729596
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: PD-L1, B7-H3
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patients must have tumors with B7-H3 & PD-L1 expression
Exclusions: Patients with symptomatic, untreated, unstable central nervous system (CNS) metastases and/or leptomeningeal disease that requires treatment – see trial for details; Patients with prior treatment of B7-H3 targeted agents for cancer
https://ClinicalTrials.gov/show/NCT03729596